Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis

Current Topics in Medicinal Chemistry

Volumn 7, Issue 5, 2007, Pages 489-498

  Tonge, Peter J ^a   Kisker, Caroline ^b   Slayden, Richard A ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Cell wall; Diphenyl ether; Enoyl reductase; Fatty acid biosynthesis; InhA; Isoniazid; Mycobacterium; Mycolic acid; Triclosan

Indexed keywords

5 BUTYL 2 PHENOXYPHENOL; 5 ETHYL 2 PHENOXYPHENOL; 5 HEXYL 2 PHENOXYPHENOL; 5 OCTYL 2 PHENOXYPHENOL; 5 PENTYL 2 PHENOXYPHENOL; 5 TETRADECYL 2 PHENOXYPHENOL; ANTIINFECTIVE AGENT; CERULENIN; DIPHENYL ETHER; ENOYL REDUCTASE INHIBITOR; ENZYME INHIBITOR; ETHAMBUTOL; FATTY ACID; ISONIAZID; PIPERAZINE DERIVATIVE; THIENODIAZABORINE; THIOLACTOMYCIN; TRICLOSAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 33947651030     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780059781     Document Type: Review

References (78)

1. Kochi, A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991, 72 (1), 1-6.
2. Bloom, B. R.; Murray, C. J. Tuberculosis: commentary on a reemergent killer. Science 1992, 257 (5073), 1055-64.
3. Perlman, D. C.; ElSadr, W. M.; Heifets, L. B.; Nelson, E. T.; Matts, J. P.; Chirgwin, K.; Salomon, N.; Telzak, E. E.; Klein, O.; Kreiswirth, B. N.; Musser, J. M.; Hafner, R. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Aids 1997, 11 (12), 1473-1478.
4. Rattan, A.; Kalia, A.; Ahmad, N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg. Infect. Dis. 1998, 4 (2), 195-209.
5. Snider, D. E. Jr.; Roper, W. L. The new tuberculosis. N. Engl. J. Med. 1992, 326 (10), 703-705.
6. Gupta, R.; Espinal, M. A.; Raviglione, M. C. Tuberculosis as a major global health problem in the 21st century: a WHO perspective. Semin. Respir. Crit. Care Med. 2004, 25 (3), 245-53.
7. Brennan, P. J.; Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem. 1995, 64, 29-63.
8. Lee, R. E.; Brennan, P. J.; Besra, G. S. Mycobacterium tuberculosis cell envelope. Curr. Top. Microbiol. Immunol. 1996, 215, 1-27.
9. Russell, D. G.; Mwandumba, H. C.; Rhoades, E. E. Mycobacterium and the coat of many lipids. J. Cell. Biol. 2002, 158 (3), 421-6.
10. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358 (6387), 591-3.
11. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs WR, J. r. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263 (5144), 227-30.
12. Johnsson, K.; Schultz, P. G. Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 1994, 116, 7425-7426.
13. Johnsson, K.; King, D. S.; Schultz, P. G. Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis. J. Am. Chem. Soc. 1995, 117, 5009-5010.
14. Basso, L. A.; Zheng, R. J.; Blanchard, J. S. Kinetics of inactivation of WT and C243S mutant of Mycobacterium tuberculosis enoyl reductase by activated isoniazid. J. Am. Chem. Soc. 1996, 118 (45), 11301-11302.
15. Dessen, A.; Quemard, A.; Blanchard, J. S.; Jacobs WR, J. r.; Sacchettini, J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995, 267 (5204), 1638-41.
16. Quemard, A.; Sacchettini, J. C.; Dessen, A.; Vilcheze, C.; Bittman, R.; Jacobs, W. R. Jr.; Blanchard, J. S. Enzymatic Characterization of the Target for Isoniazid in Mycobacterium tuberculosis. Biochemistry 1995, 34 (26), 8235-8241.
17. Quemard, A.; Dessen, A.; Sugantino, M.; Jacobs, W. R. Jr.; Sacchettini, J. C.; Blanchard, J. S. Binding of Catalase-Peroxidase-Activated Isoniazid to Wild-Type and Mutant Mycobacterium tuberculosis Enoyl - ACP Reductases. J. Am. Chem. Soc. 1996, 118 (6), 1561-1562.
18. Rozwarski, D. A.; Grant, G. A.; Barton, D. H. R.; Jacobs WR, J. r.; Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279 (5347), 98-102.
19. Stoeckle, M. Y.; Guan, L.; Riegler, N.; Weitzman, I.; Kreiswirth, B.; Kornblum, J.; Laraque, F.; Riley, L. W. Catalase-peroxidase gene sequences in isoniazid-sensitive and - resistant strains of Mycobacterium tuberculosis from New York City. J. Infect. Dis. 1993, 168 (4), 1063-1065.
20. Heym, B.; Honore, N.; Truffot-Pernot, C.; Banerjee, A.; Schurra, C.; Jacobs WR, J. r.; van Embden, J. D.; Grosset, J. H.; Cole, S. T. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994, 344 (8918), 293-8.
21. Musser, J. M.; Kapur, V.; Williams, D. L.; Kreiswirth, B. N.; van Soolingen, D.; van Embden, J. D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and - susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 1996, 173 (1), 196-202.
22. Ramaswamy, S. V.; Reich, R.; Dou, S. J.; Jasperse, L.; Pan, X.; Wanger, A.; Quitugua, T.; Graviss, E. A. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47 (4), 1241-50.
23. Rawat, R.; Whitty, A.; Tonge, P. J. The Isoniazid-NAD Adduct is a Slow, Tight-Binding Inhibitor of InhA, the Mycobacterium Tuberculosis Enoyl Reductase; Adduct Affinity and Drug Resistance. Proc. Nat. Acad. Sci. U.S.A. 2003, 100, 13881-13886.
24. Slayden, R. A.; Lee, R. E.; Barry, C. E. 3rd, Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 2000, 38 (3), 514-25.
25. Slayden, R. A.; Barry, C. E. 3rd, The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect. 2000, 2 (6), 659-69.
26. Vilcheze, C.; Morbidoni, H. R.; Weisbrod, T. R.; Iwamoto, H.; Kuo, M.; Sacchettini, J. C.; Jacobs, W. R. Jr. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 2000, 182 (14), 4059-67.
27. Larsen, M. H.; Vilcheze, C.; Kremer, L.; Besra, G. S.; Parsons, L.; Salfinger, M.; Heifets, L.; Hazbon, M. H.; Alland, D.; Sacchettini, J. C.; Jacobs, W. R. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 2002, 46 (2), 453-66.
28. Slayden, R. A.; Barry CE, r. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis 2002, 81 (1), 1-12.
29. Kremer, L.; Dover, L. G.; Morbidoni, H. R.; Vilcheze, C.; Maughan, W. N.; Baulard, A.; Tu, S. C.; Honore, N.; Deretic, V.; Sacchettini, J. C.; Locht, C.; Jacobs, W. R.; Besra, G. S. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 2003, 278, 20547-20554.
30. Heath, R. J.; White, S. W.; Rock, C. O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 2001, 40 (6), 467-97.
31. Campbell, J. W.; Cronan, J. E. Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 2001, 55, 305-32.
32. Heath, R. J.; White, S. W.; Rock, C. O. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 2002, 58 (6), 695-703.
33. Nomura, S.; Horiuchi, T.; Omura, S.; Hata, T. The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast. J. Biochem. 1972, 71 (5), 783-96.
34. Noto, T.; Miyakawa, S.; Oishi, H.; Endo, H.; Okazaki, H. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity. J. Antibiot. 1982, 35 (4), 401-10.
35. Tsay, J. T.; Rock, C. O.; Jackowski, S. Overproduction of beta-ketoacyl-acyl carrier protein synthase I imparts thiolactomycin resistance to Escherichia coli K-12. J. Bacteriol. 1992, 174 (2), 508-13.
36. Wallace, K. K.; Lobo, S.; Han, L.; McArthur, H. A.; Reynolds, K. A. In vivo and in vitro effects of thiolactomycin on fatty acid biosynthesis in Streptomyces collinus. J. Bacteriol. 1997, 179 (12), 3884-91.
37. Schweizer, H. P. Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. Antimicrob. Agents Chemother. 1998, 42 (2), 394-8.
38. Choi, K. H.; Kremer, L.; Besra, G. S.; Rock, C. O. Identification and substrate specificity of beta -ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J. Biol. Chem. 2000, 275 (36), 28201-7.
39. Kremer, L.; Douglas, J. D.; Baulard, A. R.; Morehouse, C.; Guy, M. R.; Alland, D.; Dover, L. G.; Lakey, J. H.; Jacobs, W. R. Jr.; Brennan, P. J.; Minnikin, D. E.; Besra, G. S. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 2000, 275 (22), 16857-64.
40. Price, A. C.; Choi, K. H.; Heath, R. J.; Li, Z.; White, S. W.; Rock, C. O. Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem. 2001, 276 (9), 6551-9.
41. Schaeffer, M. L.; Agnihotri, G.; Volker, C.; Kallender, H.; Brennan, P. J.; Lonsdale, J. T. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. J. Biol. Chem. 2001, 276 (50), 47029-37.
42. Douglas, J. D.; Senior, S. J.; Morehouse, C.; Phetsukiri, B.; Campbell, I. B.; Besra, G. S.; Minnikin, D. E. Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. Microbiology 2002, 148 (Pt 10), 3101-9.
43. Jackowski, S.; Zhang, Y. M.; Price, A. C.; White, S. W.; Rock, C. O. A missense mutation in the fabB (beta-ketoacyl-acyl carrier protein synthase I) gene confers thiolactomycin resistance to Escherichia coli. Antimicrob. Agents Chemother. 2002, 46 (5), 1246-52.
44. Bergler, H.; Wallner, P.; Ebeling, A.; Leitinger, B.; Fuchsbichler, S.; Aschauer, H.; Kollenz, G.; Hogenauer, G.; Turnowsky, F. Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli. J. Biol. Chem. 1994, 269 (8), 5493-5496.
45. Turnowsky, F.; Fuchs, K.; Jeschek, C.; Hogenauer, G. envM genes of Salmonella typhimurium and Escherichia coli. J. Bacteriol. 1989, 171 (12), 6555-65.
46. Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Hawkes, T. R.; Rice, D. W. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996, 274 (5295), 2107-2110.
47. de Boer, G. J.; Pielage, G. J. A.; Nijkamp, H. J. J.; Slabas, A. R.; Rafferty, J. B.; Baldock, C.; Rice, D. W.; Stuitje, A. R. Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine. Mol. Micro. 1999, 31 (2), 443-450.
48. Heath, R. J.; Yu, Y. T.; Shapiro, M. A.; Olson, E.; Rock, C. O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 1998, 273 (46), 30316-20.
49. McMurry, L. M.; Oethinger, M.; Levy, S. B. Triclosan targets lipid synthesis. Nature 1998, 394 (6693), 531-2.
50. Heath, R. J.; Rubin, J. R.; Holland, D. R.; Zhang, E.; Snow, M. E.; Rock, C. O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274 (16), 11110-4.
51. Levy, C. W.; Roujeinikova, A.; Sedelnikova, S.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. Molecular basis of triclosan activity. Nature 1999, 398 (6726), 383-4.
52. McMurry, L. M.; McDermott, P. F.; Levy, S. B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 1999, 43 (3), 711-3.
53. Qiu, X. Y.; Janson, C. A.; Court, R. I.; Smyth, M. G.; Payne, D. J.; Abdel-Meguid, S. S. Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci. 1999, 8 (11), 2529-2532.
54. Roujeinikova, A.; Levy, C. W.; Rowsell, S.; Sedelnikova, S.; Baker, P. J.; Minshull, C. A.; Mistry, A.; Colls, J. G.; Camble, R.; Stuitje, A. R.; Slabas, A. R.; Rafferty, J. B.; Pauptit, R. A.; Viner, R.; Rice, D. W. Crystallographic analysis of triclosan bound to enoyl reductase. J. Mol. Biol. 1999, 294 (2), 527-535.
55. Stewart, M. J.; Parikh, S.; Xiao, G.; Tonge, P. J.; Kisker, C. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 1999, 290, 859-865.
56. Ward, W. H. J.; Holdgate, G. A.; Rowsell, S.; McLean, E. G.; Pauptit, R. A.; Clayton, E.; Nichols, W. W.; Colls, J. G.; Minshull, C. A.; Jude, D. A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N. J.; Britton, C. J.; Taylor, I. W. F. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999, 38 (38), 12514-12525.
57. Parikh, S. L.; Xiao, G.; Tonge, P. J. Inhibition of InhA, the enoyl-reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 2000, 39 (26), 7645-7650.
58. Moir, D. T. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 2005, 5 (3), 297-305.
59. Heerding, D. A.; Chan, G.; DeWolf, W. E.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; McManus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith, W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C.; Huffman, W. F. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 2001, 11 (16), 2061-5.
60. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf Jr, W. E. Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C.; Huffman, W. F. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 2002, 46 (10), 3118-24.
61. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E. Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 2002, 45 (15), 3246-56.
62. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf Jr, W. E.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole Naphthyridinones as Inhibitors of Bacterial Enoyl-ACP Reductases FabI and FabK. J. Med. Chem. 2003, 46 (9), 1627-35.
63. Tasdemir, D.; Guner, N. D.; Perozzo, R.; Brun, R.; Donmez, A. A.; Calis, I.; Ruedi, P. Anti-protozoal and plasmodial FabI enzyme inhibiting metabolites of Scrophularia lepidota roots. Phytochemistry 2005, 66 (3), 355-62.
64. Freundlich, J. S.; Anderson, J. W.; Sarantakis, D.; Shieh, H. M.; Yu, M.; Valderramos, J. C.; Lucumi, E.; Kuo, M.; Jacobs, W. R. Jr.; Fidock, D. A.; Schiehser, G. A.; Jacobus, D. P.; Sacchettini, J. C. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4′-substituted triclosan derivatives. Bioorg. Med. Chem. Lett. 2005, 15 (23), 5247-52.
65. Kirmizibekmez, H.; Calis, I.; Perozzo, R.; Brun, R.; Donmez, A. A.; Linden, A.; Ruedi, P.; Tasdemir, D. Inhibiting activities of the secondary metabolites of Phlomis brunneogaleata against parasitic protozoa and plasmodial enoyl-ACP Reductase, a crucial enzyme in fatty acid biosynthesis. Planta. Med. 2004, 70 (8), 711-7.
66. Kuo, M. R.; Morbidoni, H. R.; Alland, D.; Sneddon, S. F.; Gourlie, B. B.; Staveski, M. M.; Leonard, M.; Gregory, J. S.; Janjigian, A. D.; Yee, C.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W. R. Jr.; Sacchettini, J. C.; Fidock, D. A. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 2003, 278, 20851-20859.
67. Perozzo, R.; Kuo, M.; Sidhu, A. S.; Valiyaveettil, J. T.; Bittman, R.; Jacobs, W. R. Jr.; Fidock, D. A.; Sacchettini, J. C. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem. 2002, 277 (15), 13106-14.
68. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7 (2), 167-73.
69. Sivaraman, S.; Sullivan, T. J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P. J. Inhibition of the Bacterial Enoyl Reductase FabI by Triclosan: A Structure-Reactivity Analysis of FabI Inhibition by Triclosan Analogs. J. Med Chem. 2004, 47, 509-518.
70. Sivaraman, S.; Zwahlen, J.; Bell, A. F.; Hedstrom, L.; Tonge, P. J. Structure-Activity Studies of the Inhibition of FabI, the Enoyl Reductase from Escherichia coli, by Triclosan: Kinetic Analysis of Mutant FabIs. Biochemistry 2003, 42 (15), 4406-4413.
71. Sullivan, T. J.; Truglio, J. J.; Boyne, M. E.; Novichenok, P.; Zhang, X.; Stratton, C. F.; Li, H.-J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R. A.; Kisker, C.; Tonge, P. J. High Affinity InhA Inhibitors With Activity Against Drug Resistant Strains of Mycobacterium Tuberculosis. ACS Chem. Biol. 2006, 1, 43-53.
72. Rozwarski, D. A.; Vilcheze, C.; Sugantino, M.; Bittman, R.; Sacchettini, J. C. Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate. J. Biol. Chem. 1999, 274, 15582-15589.
73. Dai, C. Y.; Fu, G. C. The first general method for palladium-catalyzed Negishi cross-coupling of aryl and vinyl chlorides: Use of commercially available Pd(P(t-BU)(3))(2) as a catalyst. J. Am. Chem. Soc. 2001, 123 (12), 2719-2724.
74. Neumeyer, J. L.; Baindur, N.; Yuan, J.; Booth, G.; Seeman, P.; Niznik, H. B. Development of a High-Affinity and Stereoselective Photoaffinity Label for the D-1 Dopamine Receptor - Synthesis and Resolution of 7-(I-125)Iodo-8-Hydroxy-3-Methyl-1-(4′-Azidophenyl)-2,3,4,5- Tetrahydro-1h-3-Benzazepine. J. Med. Chem. 1990, 33 (2), 521-526.
75. Marcoux, J. F.; Doye, S.; Buchwald, S. L. A general copper-catalyzed synthesis of diaryl ethers. J. Am. Chem. Soc. 1997, 119 (43), 10539-10540.
76. Betts, J. C.; McLaren, A.; Lennon, M. G.; Kelly, F. M.; Lukey, P. T.; Blakemore, S. J.; Duncan, K. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47 (9), 2903-13.
77. Wilson, M.; DeRisi, J.; Kristensen, H. H.; Imboden, P.; Rane, S.; Brown, P. O.; Schoolnik, G. K. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (22), 12833-8.
78. Tonge, P. J. Another brick in the wall. Nat. Struct. Biol. 2000, 7 (2), 94-96.